Soleno Therapeutics, Inc. (SLNO)

$31.67

+2.73 (+9.43%)
Rating:
Recommendation:
Neutral
Symbol SLNO
Price $31.67
Beta -1.382
Volume Avg. 1.19M
Market Cap 965.916M
Shares () -
52 Week Range 0.85-31.72
1y Target Est -
DCF Unlevered SLNO DCF ->
DCF Levered SLNO LDCF ->
ROE -258.52% Strong Sell
ROA -49.46% Strong Sell
Operating Margin -
Debt / Equity 2.02% Neutral
P/E -9.87 Strong Sell
P/B 15.60 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SLNO news


Dr. Anish Bhatnagar M.D.
Healthcare
Biotechnology
NASDAQ Capital Market

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.